SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Liver - Bilirubin Metabolism - Crigler Najjar Syndrome Written by Dr Sebastian Zeki

Crigler Najjar Syndrome

Written by Dr Sebastian Zeki Dec. absorption of bilirubin/ production of bilirubin or inc. clearance Hepatocyte transplantation Diagnosis — Treatment — Distinction of type 1 from type II disease.Type 1 is assoc. with lower [serum bilirubin] -values can overlap with type I, especially with underlying haemolysis.Phenobarbital can reduce type II; not type I.No conjugated bilirubin in type 1.DNA extracted from any tissue can make the diagnosis. Gene therapy —By introduction of a normal bilirubin-UGT gene (UGT1A1).Ex vivo gene transduction — Harvest hepatocytes from patient, culture and insert normal gene. DifficultVector-mediated gene delivery.------Adenoviral vectors — Locate to liver, transfer trangene to non-dividing cells. But need repeated injections which induce immune response.------SV40 and lentiviruses — Less immunogenicity appears to be negligible, dont localise to liver unless given via portal veinReceptor-mediated gene delivery to the liver —Using carrier proteins- short livedSite-directed gene conversion — By aligning specific sequences with a mismatch so host gene repair mechanism used. Calcium phosphate supplementation —Traps unconjugated bilirubin in gut, lowers the [bilirubin] by 20-50 %.Orlistat —Captures intestinal unconjugated bilirubin.Inhibition of bilirubin production —Heme oxygenase, eg tin-protoporphyrin or tin-mesoporphyrin, inhibits enzyme- better in neonates than adults in which the effect is short lived.Plasmapheresis —Most efficient way to deal with a crisis Liver transplantation This has resulted in long-term survival and is the only curative therapy. Phototherapy Most patients treated with this can survive past puberty, but get kernicterus later. No treatment: Most dead in 18mWith treatment25% brain damage Isolated unconjugated hyper-bilirubin few days after birth Type 1 DiseaseThis is due to mutations in UGT1A1 gene.Because Gilbert’s is so common, patients can have Gilbert’s with Crigler- Najaar which can lead to severe hyperbilirubinemia, since the activity of the normal allele is reduced to about 30 % of normal.Gilbert’s with Crigler-Najaar explains the frequent finding of intermediate levels of hyperbili-rubinemia in the family members of patients with Crigler-Najjar syndrome, both types I and II. Type 2 DiseaseThis is less marked (serum bilirubin <20 mg/dL).50% are icteric at <1 year.Bilirubin ranges from 8-18 mg/dL.UGT defect is much less severe than in type I disease (residual bilirubin-UGT activity of 2-8 % vs up to 38%).The enzyme is catalytically effective only if hyperbilirubinemia is present (low affinity).Only 50 % of bilirubin is conjugated and excreted into bile.Conjugate is mainly bilirubin monoglucu-roniderather than diglucuronide.The molecular defect is in one of 5 exons coding bilirubin-UGT.Unconjugated hyperbilirubinemia is < 20 mg/dL but can rise to 40 mg/dL if fasting/ intercurrent illness.Other LFT’s normal.Only treat high bilirubin if affects QOL -less likely to get neuro problems.Treat with phenobarbital or clofibrate which reduces serum bilirubin levels by >25 %.Patients respond in 2-3 weeks. Crigler-Najjar syndrome

Related Stories

Different methods in predicting mortality of pediatric intensive care units sepsis in Southwest China

Clinical outcomes of ABCB4 heterozygosity in infants and children with cholestatic liver disease

Bilirubin Down-Regulates Oxidative Stress and Fibroblast Growth Factor 23 Expression in UMR106 Osteoblast-Like Cells

Health effects of exposure to urban ambient particulate matter: A spatial-statistical study on 3rd-trimester pregnant women

Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis